SCHEMBL30345232

SCHEMBL30345232

Fc1cccnc1C(F)(F)F

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NFE2L2 Q16236 2/20 0.38
HTT P42858 1/20 0.36
HSD17B10 Q99714 1/20 0.36
KDM4E B2RXH2 3/20 0.35
MPI P34949 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35
ELANE P08246 1/20 0.34
LMNA P02545 1/20 0.34
EPHX2 P34913 1/20 0.33
HCAR2 Q8TDS4 1/20 0.33
NPC1 O15118 1/20 0.33
HSD11B1 P28845 1/20 0.33
NAPRT Q6XQN6 1/20 0.33
MAT2A P31153 1/20 0.33
DHODH Q02127 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2C19 P33261 1/20 0.33
GRM4 Q14833 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9065844 1.00 NFE2L2 (0.38) NFE2L2HTTHSD17B10KDM4EMPI
Hydrochloric Acid SCHEMBL28284403 0.98 NFE2L2 (0.37) NFE2L2HTTHSD17B10KDM4EMPI
SCHEMBL10354469 0.82 NFE2L2 (0.33) NFE2L2KDM4EMPIL3MBTL1NPC1
SCHEMBL28068132 0.79 NFE2L2 (0.36) NFE2L2KDM4EMPIL3MBTL1NPC1
SCHEMBL5958366 0.79 TRPV1 (0.37) NFE2L2HTTKDM4EMPIL3MBTL1
SCHEMBL10763328 0.79 NFE2L2 (0.35) NFE2L2KDM4EMPIL3MBTL1
SCHEMBL30342164 0.77 KDM4E (0.31) KDM4ELMNA
SCHEMBL25189938 0.77 L3MBTL1 (0.34) NFE2L2KDM4EMPIL3MBTL1HDAC6
SCHEMBL16914429 0.76 PSMD14 (0.45) HTTHSD17B10KDM4EL3MBTL1HDAC6
SCHEMBL13286511 0.76 HTT (0.36) HTTHSD17B10KDM4EL3MBTL1HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240246908-A1 TEAD INHIBITORS ORION CORPORATION (FI) 2024-07-25 US disclosed
US-11802122-B2 2-oxoimidazolidine-4-carboxamides as NAv1.8 inhibitors MERCK SHARP & DOHME LLC (US) 2023-10-31 US disclosed
CN-116134018-A 2-oxoimidazolidine-4-carboxamide as NAV1.8 inhibitor 默沙东有限责任公司 2023-05-16 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240246908-A1 TEAD INHIBITORS TEAD3, TEAD1, TEAD2 NFE2L2 2500/4885HTT 3852/4885HSD17B10 2329/4885
US-11802122-B2 2-oxoimidazolidine-4-carboxamides as NAv1.8 inhibitors SCN8A, TRPV1, SCN2A NFE2L2 596/4885HTT 3897/4885HSD17B10 4178/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.